I think the point is simply that IV administration has not been established pre-clinically with any significance. Hence his first paragraph... "I'm wondering if anyone has addressed the fact that there is limited preclinical evidence that has demonstrated a significant benefit from intravenous administration of CF33 either as a single agent or in combination with an anti-PDL1 in every murine model tested?"
Now if there is limited preclinical (animal) evidence of IV admin, then may not work in humans, through IV route.
IMU Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)